問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

E-DA Hospital (在職)

Division of Hematology & Oncology

E-DA Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

廖浚凱
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖浚凱

List

73Cases

2014-08-01 - 2024-06-20

Phase III

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

  • Condition/Disease

    Multiple Myeloma Following Autologous Stem Cell Transplant

  • Test Drug

    Ixazomib Citrate (MLN9708)

Participate Sites
5Sites

Terminated5Sites

2021-11-01 - 2030-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-09-01 - 2025-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-12-25 - 2025-07-31

Phase III

A randomized, double-blind, placebo-controlled, active-comparator, multicenter, phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

  • Condition/Disease

    diffuse large B-cell lymphoma (DLBCL)

  • Test Drug

    Brentuximab Vedotin, Lenalidomide,Rituximab

Participate Sites
7Sites

Recruiting7Sites

2016-06-01 - 2019-05-31

Phase I

A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects with Advanced Tumors

  • Condition/Disease

    Advanced Tumors

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Terminated6Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

侯明模
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-07-31 - 2022-06-30

Phase II/III

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    ASP2215

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2017-01-13 - 2023-12-31

Phase III

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission

  • Condition/Disease

    Acute Myeloid Leukemia

  • Test Drug

    ASP2215

Participate Sites
7Sites

Terminated5Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2019-01-01 - 2026-04-30

Phase III

A Phase 3, Randomized, Open-label, Parallel-controlled, Multi-center Study Comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 1 Prior Line of Treatment

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    TJ202

Participate Sites
5Sites

Terminated5Sites

2019-09-15 - 2027-05-31

Phase I/II

A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent to Subjects with Refractory or Relapsed Non-Hodgkin's Lymphoma

  • Condition/Disease

    Refractory or Relapsed Non-Hodgkin's Lymphoma

  • Test Drug

    CHO-H01

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2021-07-26 - 2025-09-08

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB